Euroopa Liit - eesti - EMA (European Medicines Agency)

stada arzneimittel ag - budesonide, micronised - glomerulonephritis, iga - antidiarrheals, soole põletikuvastased / antiinfective ained - kinpeygo is indicated for the treatment of primary immunoglobulin a (iga) nephropathy (igan) in adults at risk of rapid disease progression with a urine protein-to-creatinine ratio (upcr) ≥1. 5 g/gram.

Euroopa Liit - eesti - EMA (European Medicines Agency)

stada arzneimittel ag - ranibizumab - wet macular degeneration; macular edema; diabetic retinopathy; diabetes complications - oftalmoloogilised vahendid - ximluci is indicated in adults for:the treatment of neovascular (wet) age-related macular degeneration (amd)the treatment of visual impairment due to diabetic macular oedema (dme)the treatment of proliferative diabetic retinopathy (pdr)the treatment of visual impairment due to macular oedema secondary to retinal vein occlusion (branch rvo or central rvo)the treatment of visual impairment due to choroidal neovascularisation (cnv).

Euroopa Liit - eesti - EMA (European Medicines Agency)

stada arzneimittel ag - bevatsizumab - colorectal neoplasms; breast neoplasms; ovarian neoplasms; fallopian tube neoplasms; peritoneal neoplasms; carcinoma, non-small-cell lung; carcinoma, renal cell; uterine cervical neoplasms - antineoplastilised ained - oyavas in combination with fluoropyrimidine based chemotherapy is indicated for treatment of adult patients with metastatic carcinoma of the colon or rectum. oyavas in combination with paclitaxel is indicated for first line treatment of adult patients with metastatic breast cancer. lisateavet inimese epidermaalse kasvufaktori retseptori 2 (her2) seisundi kohta vt palun 5. jaotisest. oyavas in combination with capecitabine is indicated for first line treatment of adult patients with metastatic breast cancer in whom treatment with other chemotherapy options including taxanes or anthracyclines is not considered appropriate. patients who have received taxane and anthracycline containing regimens in the adjuvant setting within the last 12 months should be excluded from treatment with oyavas in combination with capecitabine. her2 staatuse kohta lisateabe saamiseks lugege palun 5. jaotist. oyavas, in addition to platinum based chemotherapy, is indicated for first line treatment of adult patients with unresectable advanced, metastatic or recurrent non small cell lung cancer other than predominantly squamous cell histology. oyavas, in combination with erlotinib, is indicated for first line treatment of adult patients with unresectable advanced, metastatic or recurrent non squamous non small cell lung cancer with epidermal growth factor receptor (egfr) activating mutations (see section 5. oyavas in combination with interferon alfa 2a is indicated for first line treatment of adult patients with advanced and/or metastatic renal cell cancer. oyavas, in combination with carboplatin and paclitaxel is indicated for the front line treatment of adult patients with advanced (international federation of gynecology and obstetrics (figo) stages iii b, iii c and iv) epithelial ovarian, fallopian tube, or primary peritoneal cancer (see section 5. oyavas, in combination with carboplatin and gemcitabine or in combination with carboplatin and paclitaxel, is indicated for treatment of adult patients with first recurrence of platinum sensitive epithelial ovarian, fallopian tube or primary peritoneal cancer who have not received prior therapy with bevacizumab or other vegf inhibitors or vegf receptor–targeted agents. oyavas, in combination with topotecan, or pegylated liposomal doxorubicin is indicated for the treatment of adult patients with platinum resistant recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who received no more than two prior chemotherapy regimens and who have not received prior therapy with bevacizumab or other vegf inhibitors or vegf receptor targeted agents (see section 5. oyavas, in combination with paclitaxel and cisplatin or, alternatively, paclitaxel and topotecan in patients who cannot receive platinum therapy, is indicated for the treatment of adult patients with persistent, recurrent, or metastatic carcinoma of the cervix (see section 5.

Euroopa Liit - eesti - EMA (European Medicines Agency)

stada arzneimittel ag - teriparatiid - osteoporoos - kaltsiumi homöostaas - movymia on näidustatud täiskasvanutel. osteoporoosi ravi postmenopausis naistel ja meestel, kellel on suurem luumurdude risk. postmenopausaalsetel naistel on selgelt ja selgroogsete luumurdude, kuid mitte puusaluumurdude esinemissageduse märkimisväärne vähenemine. ravi osteoporoosi seostatakse pidevat süsteemset glükokortikoidi ravi naiste ja meeste suurenenud risk luumurdude.

Eesti - eesti - Ravimiamet

stada arzneimittel ag - gemtsitabiin - infusioonilahuse kontsentraat - 38mg 1ml 39.5ml 1tk; 38mg 1ml 5.26ml 1tk; 38mg 1ml 52.6ml 1tk; 38mg 1ml 26.3ml 1tk

Eesti - eesti - Ravimiamet

stada arzneimittel ag - sumatriptaan - tablett - 100mg 16tk; 100mg 3tk; 100mg 4tk; 100mg 2tk; 100mg 24tk; 100mg 8tk; 100mg 6tk; 100mg 18tk; 100mg 1tk

Eesti - eesti - Ravimiamet

stada arzneimittel ag - sumatriptaan - tablett - 50mg 4tk; 50mg 18tk; 50mg 8tk; 50mg 3tk; 50mg 1tk; 50mg 6tk; 50mg 2tk

Eesti - eesti - Ravimiamet

stada arzneimittel ag - tsilostasool - tablett - 100mg 56tk; 100mg 98tk; 100mg 20tk; 100mg 30tk; 100mg 14tk

Eesti - eesti - Ravimiamet

stada arzneimittel ag - omeprasool - gastroresistentne kõvakapsel - 20mg 50tk; 20mg 90tk; 20mg 250tk; 20mg 5tk; 20mg 30tk; 20mg 280tk; 20mg 100tk; 20mg 105tk; 20mg 500tk

Eesti - eesti - Ravimiamet

stada arzneimittel ag - omeprasool - gastroresistentne kõvakapsel - 10mg 56tk; 10mg 90tk; 10mg 280tk; 10mg 60tk; 10mg 28tk; 10mg 30tk; 10mg 14tk; 10mg 98tk; 10mg 500tk; 10mg 5tk; 10mg 15tk; 10mg 100tk